- Home
- AKRO vs HCM Comparison
AKRO vs HCM Comparison
Compare AKRO & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- HCM
- Stock Information
- Founded
- AKRO 2017
- HCM 2000
- Country
- AKRO United States
- HCM Hong Kong
- Employees
- AKRO N/A
- HCM N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- AKRO Health Care
- HCM Health Care
- Exchange
- AKRO Nasdaq
- HCM Nasdaq
- Market Cap
- AKRO 2.8B
- HCM 2.5B
- IPO Year
- AKRO 2019
- HCM N/A
- Fundamental
- Price
- AKRO $39.85
- HCM $14.21
- Analyst Decision
- AKRO Strong Buy
- HCM Hold
- Analyst Count
- AKRO 9
- HCM 1
- Target Price
- AKRO $76.29
- HCM $19.00
- AVG Volume (30 Days)
- AKRO 1.1M
- HCM 82.7K
- Earning Date
- AKRO 05-16-2025
- HCM 03-19-2025
- Dividend Yield
- AKRO N/A
- HCM N/A
- EPS Growth
- AKRO N/A
- HCM N/A
- EPS
- AKRO N/A
- HCM 0.04
- Revenue
- AKRO N/A
- HCM $630,201,000.00
- Revenue This Year
- AKRO N/A
- HCM $14.86
- Revenue Next Year
- AKRO N/A
- HCM $19.54
- P/E Ratio
- AKRO N/A
- HCM $68.70
- Revenue Growth
- AKRO N/A
- HCM N/A
- 52 Week Low
- AKRO $17.86
- HCM $11.51
- 52 Week High
- AKRO $58.40
- HCM $21.92
- Technical
- Relative Strength Index (RSI)
- AKRO 44.56
- HCM 45.83
- Support Level
- AKRO $41.60
- HCM $14.18
- Resistance Level
- AKRO $46.47
- HCM $14.84
- Average True Range (ATR)
- AKRO 2.26
- HCM 0.57
- MACD
- AKRO 0.08
- HCM -0.03
- Stochastic Oscillator
- AKRO 21.84
- HCM 1.94
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.